格隆汇2月4日｜诺华制药(NVS.US)预计今年利润将出现下滑，原因是受心脏病药物诺欣妥等核心畅销 药面临仿制药竞争的进一步冲击。该公司周三表示，按固定汇率计算，核心营业收入可能出现低个位数 的降幅。销售额预计将增长低个位数。首席执行官Vas Narasimhan专注于创新药物的战略将在今年面临 考验，因为诺欣妥及其他老牌畅销药正饱受仿制药竞争对手带来的压力。目前，诺诺华正在推出一款治 疗自身免疫性皮肤病的新药，并将很快发布针对心脏病和多发性硬化症等实验性疗法的关键数据。诺华 已承诺在美国建设七个新设施，这是其扩大在美制造布局的230亿美元投资计划的一部分。其中很大一 部分将专注于放射配体疗法（RLT）——这是一种利用靶向药物将放射性同位素直接输送到肿瘤的癌症 治疗方法。 ...

Key Points Summary of 九州药业 Conference Call Company Overview - 九州药业 is transitioning from generic drugs to innovative drug services, established in 1973 and entered the pharmaceutical sector in 1985. The company began its CDMO (Contract Development and Manufacturing Organization) business in 2008 and went public in 2014 [3][4]. Industry and Business Structure - The company has achieved synergy in domestic and international production through acquisitions and self-built capabilities, including the establishment of an overseas management headquarters in Singapore and R&D platforms in Japan and Germany [2][3]. - The core revenue source is the CDMO business, which generated revenue of 22.91 billion yuan in the first half of 2025, representing a year-on-year growth of 16.27% with a gross margin of 41% [2][3]. Project Pipeline and Clientele - The project pipeline has increased from 378 in 2019 to 1,214 as of the first half of 2025, including 38 commercialized products [2][3]. - Major clients include multinational corporations (MNCs) such as Novartis, Roche, and Pfizer, with Novartis accounting for over 60% of the revenue [2][5]. Financial Performance - In the first half of 2025, the raw material drug business generated revenue of 5.23 billion yuan, maintaining a gross margin of 23% despite industry competition and price declines [2][5]. - The company expects a net profit growth of around 15% over the next three years, with a revenue increase of 4.92% and a net profit increase of 18.51% year-on-year in the first three quarters of the current year [4][5]. New Business Initiatives - The establishment of the Prince Division aims to develop new molecular types such as peptides, conjugated drugs, and small nucleic acids, creating a second growth curve [2][5]. - The company is advancing commercial production capacity for these new initiatives, including three peptide conjugation platforms and capabilities for small nucleic acid research in both China and the U.S. [5]. Market Outlook and Valuation - The company is projected to maintain a net profit growth rate of approximately 15% over the next three years, with a target price of 27 yuan based on a 21x P/E ratio for 2026 [4][5]. - The current stock price reflects a P/E ratio of about 12x for 2027, indicating a favorable investment opportunity considering the rebound in raw material prices and healthy development in small molecule CDMO [5].

Core Viewpoint - Jiuzhou Pharmaceutical is entering a growth phase driven by its CDMO platform, which leverages its expertise in small molecules and TIDES, supported by a healthy project pipeline and high order visibility [3][5]. CDMO Business - The CDMO business is the main growth engine, with a robust project funnel and high order visibility. The company provides comprehensive lifecycle services from preclinical CMC to commercial production, deeply embedded in the supply chains of major pharmaceutical companies like Novartis and Roche [3]. - Key projects such as Noxafil and Ribociclib continue to generate revenue, while the rapid growth of the partnered product Vumerity is expected to provide sustained incremental growth [3]. - As of H1 2025, the company has a rich pipeline with 38 products on the market, 90 in Phase III, and 1,086 in Phase I/II, driving steady revenue growth [3]. API Business - The company focuses on specialty APIs, optimizing processes to enhance cost advantages. It holds a strong position in the CNS and anti-infection specialty API markets [4]. - Core product prices are expected to improve as industry inventory depletion nears completion, while new product categories are being introduced, including four specialty APIs by 2025 [4]. - Continuous process optimization and reduced development cycles are helping to maintain cost advantages, with an API business gross margin of 23.26% in H1 2025, up 2.08 percentage points year-on-year [4]. Formulations and CDMO - The company has made significant strides in its formulation and CDMO business through acquisitions and the establishment of its own facilities, completing its layout for generic and innovative drug formulations [4]. - As of Q3 2025, the formulation pipeline includes 22 projects, with 8 approved and 9 submitted for approval. The CDMO business has onboarded over 10 high-quality domestic and international clients, adding more than 30 new service projects [4]. - The formulation business is expected to maintain rapid growth in the future [4]. Investment Recommendation - The company has established a one-stop CDMO platform covering small molecules, peptides, conjugates, and formulations, serving major global pharmaceutical companies and achieving localized R&D in the US, Japan, and Germany [5]. - Projected net profits for 2025-2027 are estimated at 966 million, 1.128 billion, and 1.303 billion yuan, representing year-on-year growth of 59.4%, 16.8%, and 15.4% respectively [5]. - The current stock price corresponds to PE ratios of 16, 14, and 12 for 2025-2027. Given the company's growth prospects and strong order visibility, a target price of 26.64 yuan is set, with an initial "recommend" rating [5].

Core Viewpoint - Multinational pharmaceutical companies (MNCs) are adjusting their strategies in the Chinese county market, with Novartis deciding to dissolve its county team while emphasizing its commitment to county patients [1][2]. Group 1: Novartis' County Market Strategy - Novartis is terminating its county business operations, which began in 2021, affecting nearly 1,000 county markets [1][2]. - The company has achieved significant results in the county market, establishing nearly 1,000 pharmacies across over 800 counties, focusing on various disease areas [2][3]. - Novartis' psoriasis drug, Cosentyx, has seen high penetration in county hospitals, with a sales revenue of 2.07 billion yuan in 2024, capturing 88% of the market share for psoriasis treatment [3][4]. Group 2: Industry Trends and Adjustments - Other MNCs, like AstraZeneca and Eli Lilly, are also restructuring their operations in response to the unbalanced return on investment in lower-tier markets [2][5]. - The trend of MNCs outsourcing mature products or consolidating divisions is becoming common as they focus on innovation [11][12]. - The county market remains a significant opportunity, with over 900 million people, but the return on investment is currently not favorable for MNCs [13][17]. Group 3: Challenges in the County Market - The growth of innovative drug sales in county hospitals is lagging behind urban hospitals, with only 11.2% of the market share and a growth rate of 9.5% [15][17]. - Barriers to the adoption of innovative drugs in county markets include conservative clinical practices among county doctors and limited patient payment capabilities [15][16]. - Local pharmaceutical companies have a competitive advantage in the county market, making it difficult for foreign companies to compete effectively [17][18].

Group 1 - Novartis has been actively pursuing acquisition deals over the past year to strengthen its pipeline in response to patent expirations of key drugs like heart failure therapy, Kymriah [1][2] - On October 26, Novartis announced a proposed cash acquisition of Avidity Biosciences for approximately $12 billion to enhance its treatment portfolio for rare muscle diseases [1] - Avidity's latest market capitalization is close to $6.7 billion, and Novartis has completed nearly $20 billion in potential acquisition deals over the past year [1] Group 2 - Recent acquisitions by Novartis include: - $1.1 billion for gene therapy company Kate Therapeutics in November last year [2] - $3.1 billion for Anthos Therapeutics to enhance its cardiovascular treatment line in February [2] - $1.7 billion for Regulus Therapeutics for a kidney disease therapy in April [2] - Up to $1 billion agreement with Matchpoint Therapeutics for oral drugs targeting inflammatory diseases in July [2] - $1.4 billion acquisition of Tourmaline Bio for a cardiovascular treatment drug in September [2] - These acquisitions are aimed at addressing the patent expiration crisis of key drugs, with Novartis's stock price increasing approximately 34% this year, leading to a market capitalization exceeding $275 billion [2]

Investment Rating - The report maintains a "Buy-A" investment rating for the company with a target price of 25.30 CNY for the next six months [5][7]. Core Insights - The company achieved a revenue of 4.16 billion CNY and a net profit attributable to shareholders of 748 million CNY in the first three quarters of 2025, representing year-on-year growth of 4.92% and 18.51% respectively [2][3]. - In Q3 2025, the company reported revenue of 1.29 billion CNY and a net profit of 222 million CNY, with year-on-year increases of 7.37% and 42.30% respectively, driven by stable order deliveries from core clients and stabilizing raw material prices [2][3]. - The company is building a leading global CDMO service platform, deeply serving major pharmaceutical companies like Novartis, with a significant number of projects in various clinical stages [3]. - The company has seen stable growth in sales of its specialty raw materials, with prices gradually stabilizing, indicating potential marginal improvements in its raw material business [4]. Financial Summary - The projected net profits for the company from 2025 to 2027 are expected to be 977 million CNY, 1.12 billion CNY, and 1.24 billion CNY, reflecting year-on-year growth rates of 61.3%, 14.5%, and 10.4% respectively [5][11]. - The estimated EPS for 2025 is 1.10 CNY per share, with a PE ratio of 23 times [5][11]. - The company's total market capitalization is approximately 18.44 billion CNY, with a share price of 20.73 CNY as of October 15, 2025 [7].

Group 1: Small Molecule CDMO Business - The company focuses on technological innovation to build a leading global CDMO platform for innovative drugs, serving major pharmaceutical companies like Novartis [1] - The sales of the company's Noxintin project raw materials have significantly increased, with sales growing from $507 million in 2017 to $7.822 billion in 2024, reflecting a CAGR of 47.83% [1] - In the first half of 2025, sales reached $4.618 billion, representing a year-on-year growth of 22.27% [1] Group 2: Peptide Conjugate CDMO Services - The company has established a TIDES division to expand peptide conjugate drug and small nucleic acid technology platforms, providing comprehensive CDMO services from preclinical research to commercial production [2] - The company is actively expanding its peptide production capacity, with the second phase of peptide capacity construction initiated by the end of 2024, including the expansion of OEB5 level high-activity workshops [2] Group 3: API Business - The company is strategically positioning itself in the market by focusing on specialty APIs in areas such as anti-infectives, central nervous system drugs, non-steroidal anti-inflammatory drugs, and hypoglycemic agents [3] - Sales of anti-infective APIs increased from 292.46 tons in 2021 to 325.32 tons in 2024, with a CAGR of approximately 3.61% [3] - Sales of central nervous system APIs grew from 863.34 tons in 2021 to 1003.08 tons in 2024, with a CAGR of approximately 5.13% [3] - Sales of non-steroidal APIs rose from 298.93 tons in 2021 to 368.45 tons in 2024, with a CAGR of approximately 7.22% [3] - Sales of hypoglycemic APIs increased from 328.26 tons in 2021 to 362.66 tons in 2024, with a CAGR of approximately 3.38% [3] Group 4: Investment Recommendations - The company is projected to achieve net profits attributable to shareholders of 921 million yuan, 1.052 billion yuan, and 1.158 billion yuan from 2025 to 2027, representing year-on-year growth of 52.0%, 14.2%, and 10.0% respectively [4] - Based on the average valuation of comparable A-share listed companies, a PE ratio of 23 times is assigned for 2025, with an expected EPS of 1.04 yuan per share, leading to a target price of 23.92 yuan per share in six months [4]

Investment Rating - The report assigns a "Buy-A" investment rating to the company [5] Core Views - The company is focused on building a leading innovative drug CDMO platform centered on technological innovation, providing comprehensive services to global pharmaceutical companies [13][21] - The sales of the company's key product, Entresto, have shown significant growth, with sales increasing from $507 million in 2017 to $7.822 billion in 2024, reflecting a CAGR of 47.83% [49] - The company is expanding its capabilities in peptide conjugates and small nucleic acid technologies, enhancing its TIDES business [2][50] Summary by Sections 1. Company Overview - The company specializes in small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drug R&D and production, offering a one-stop solution from preclinical CMC to commercialization [13] - The management team possesses international experience and a strong background in pharmaceuticals, which supports the company's expansion in the innovative drug CDMO sector [17] 2. Business Segments Small Molecule CDMO - The company has established a leading technology platform to support global pharmaceutical companies, particularly in supplying raw materials for key products like Entresto [3][49] Peptide Conjugate CDMO - The TIDES division is actively expanding its peptide production capacity, with significant investments made to meet growing customer demands [2][50] API Business - The company has strategically positioned itself in the market for specialty APIs, including anti-infectives, CNS drugs, NSAIDs, and antidiabetic drugs, with stable sales growth across these categories [3][55] 3. Financial Projections - The company is projected to achieve net profits of 921 million, 1.052 billion, and 1.158 billion yuan from 2025 to 2027, with respective growth rates of 52.0%, 14.2%, and 10.0% [4][62] - Revenue is expected to grow from 5.635 billion yuan in 2025 to 6.711 billion yuan in 2027, reflecting a steady increase in demand for its services [62] 4. Market Dynamics - The demand for CDMO services is anticipated to recover due to ongoing investments in innovative drug development, particularly in oncology, hypertension, and weight loss sectors [35] - The company has established long-term partnerships with major pharmaceutical firms, which provides a solid foundation for future growth [41]

Market Review - The CITIC Pharmaceutical Index increased by 3.91%, outperforming the CSI 300 Index by 2.82 percentage points, ranking second among CITIC's 30 primary industries [5] - The top ten stocks by increase included: Borui Pharmaceutical (42.35%), Lifespring Pharmaceutical (41.68%), and Nanjing New Pharmaceutical (34.95%) [4][5] - The bottom ten stocks by decrease included: *ST Suwu, *ST Weiming, and Haobo Pharmaceutical, with declines ranging from -16.82% to -31% [4][5] Sector Insights and Investment Strategy - The pharmaceutical sector is currently undervalued, with public funds (excluding pharmaceutical funds) having low allocations to this sector. The outlook for the pharmaceutical industry in 2025 remains optimistic due to macroeconomic factors and the growth potential of major products [9] - In the innovative drug sector, there is a shift from quantity to quality, emphasizing differentiated products and internationalization. Companies that can deliver profitable products are expected to perform well [9] - The medical device market is seeing a recovery in bidding volumes, particularly in imaging equipment, and there are ongoing updates in home medical devices supported by subsidy policies [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas financing and a bottoming out in domestic financing, indicating a potential for high profit elasticity in the long term [9] Industry and Company Events - The 11th batch of national procurement products was officially released, including 55 varieties, with a total hospital sales amount of 32.772 billion yuan for 2024, averaging 5.96 million yuan per product [16][15] - The procurement list has seen a reduction of 7 products compared to the previous batch, with a total of 492 products included in the first eleven batches [15][16] - The impact of the procurement on domestic companies is limited, as the sales contribution of affected products to total revenue is relatively small [18] - The procurement process has clarified selection criteria, which may reduce disputes over certain products and improve company valuations over time [24][25]

Investment Rating - The investment rating for the pharmaceutical industry is "Outperform" [2] Core Insights - Overall revenue growth for pharmaceutical companies has slowed down, with Eli Lilly and Novo Nordisk showing significant increases of 45% and 18% respectively in Q1 2025, while other companies like GSK and Merck faced low single-digit growth or declines [3][5] - The U.S. drug price reform and uncertain macroeconomic environment are impacting the industry, with the Trump administration's executive order promoting "Most Favored Nation" pricing potentially reducing the pricing power of large pharmaceutical companies [3][7] - The next five years will see several blockbuster drugs facing patent expirations, prompting pharmaceutical companies to pursue business development (BD) transactions to enhance revenue and fill pipeline gaps [3][13] Summary by Sections 01 Overview of Q1 2025 Performance - The top 15 pharmaceutical companies had a combined R&D expenditure of $31.8 billion in Q1 2025, reflecting a year-on-year increase of 0.6% [8] 02 Revenue and Guidance - Eli Lilly reported Q1 2025 revenue of $12.7 billion, a 45% increase year-on-year, with a full-year guidance of $58.0 billion to $61.0 billion [5] - Pfizer's revenue decreased by 6% to $13.7 billion in Q1 2025, with a full-year guidance of $61.0 billion to $64.0 billion [6] 03 Drug Price Reform and Macro Environment - The Trump administration's executive order aims to provide U.S. patients with "Most Favored Nation" pricing, which could pressure drug prices downward [7] - A proposed budget plan by the Republican party includes significant cuts to Medicaid, potentially impacting pharmaceutical revenues [7] 04 Upcoming Patent Expirations - Several key products are approaching patent expiration, including Eli Lilly's Tirzepatide and JNJ's Invega Sustenna, which could lead to increased competition and revenue challenges [13][14] 05 Recent Business Development Projects - Notable recent BD transactions include JNJ's acquisition of IntraCellular for $14.6 billion to enhance its pipeline in mental health treatments [15][16]